Compare Amgen, Inc. (AMGN) vs Western Union Co (WU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Western Union Co — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Western Union Co trades at $7.85 (market cap $2.45B). The key difference: Amgen, Inc. is far larger — about 80× Western Union Co's market cap, and Western Union Co pays the higher dividend (11.99%). Which is the better fit depends on your goals.
| AMGN | WU | |
|---|---|---|
Market Cap | $196.12B | $2.45B |
Sector | Health | Technology |
52-Week High | $388.16 | $10.28 |
52-Week Low | $271.18 | $7.04 |
Enterprise Value | $241.41B | $2.14B |
Dividend Yield | 2.77% | 11.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Western Union (WU) trades at $7.84, up 0.26% on the day, with a bearish technical signal despite recent positive earnings beats. The stock shows strong profitability with a 10.88% net margin and attractive valuation ratios, including a P/E of 5.76. Recent news highlights strategic partnerships, such as the integration with Total Wireless, expanding its digital payment reach.
The outlook is mixed; low valuations and dividend yield present opportunity, but declining revenue, a recent earnings miss, and high debt pose risks. Analyst sentiment is cautious with only 12.5% buy ratings. Investors should weigh the value proposition against execution challenges in a competitive money transfer landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
